Law360 (March 25, 2011, 2:04 PM EDT) -- Par Pharmaceutical Cos. Inc. filed suit Wednesday in Pennsylvania seeking declaratory judgment that its proposed generic version of epilepsy treatment Keppra XR doesn't infringe UCB Pharma SA's patents covering the drug.
Par's submission of an abbreviated new drug application for permission to manufacture generic oral levetiracetam extended release tablets does not infringe U.S. Patent Numbers 7,858,122 and 7,863,316 because the patents are invalid and unenforceable, the plaintiff claims in a complaint filed in the U.S. District Court for the Eastern District of Pennsylvania.
The asserted patents, both titled "Extended release formulation of levetiracetam," are owned by Brussels-based UCB Pharma through assignment...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!